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Melatonin is a highly pleiotropic signaling molecule, which is released as a hormone of the pineal gland predominantly during
night. Melatonin secretion decreases during aging. Reduced melatonin levels are also observed in various diseases, such as types
of dementia, some mood disorders, severe pain, cancer, and diabetes type 2. Melatonin dysfunction is frequently related to
deviations in amplitudes, phasing, and coupling of circadian rhythms. Gene polymorphisms of melatonin receptors and circadian
oscillator proteins bear risks for several of the diseases mentioned. A common symptom of insuﬃcient melatonin signaling is
sleep disturbances. It is necessary to distinguish between symptoms that are curable by short melatonergic actions and others that
require extended actions during night. Melatonin immediate release is already eﬀective, at moderate doses, for reducing diﬃculties
offallingasleeporimprovingsymptomsassociatedwithpoorlycoupledcircadianrhythms,includingseasonalaﬀectiveandbipolar
disorders. For purposes of a replacement therapy based on longer-lasting melatonergic actions, melatonin prolonged release and
synthetic agonists have been developed. Therapies with melatonin or synthetic melatonergic drugs have to consider that these
agents do not only act on the SCN, but also on numerous organs and cells in which melatonin receptors are also expressed.
1.Introduction
Melatonin (N-acetyl-5-methoxytryptamine) has been dis-
coveredasahormoneofthepinealgland,butitismeanwhile
knowntobealsosynthesizedinvariousotherorgans,tissues,
and cells [1–3]. Pineal melatonin is secreted, in young and
middle-aged individuals, in a circadian fashion, with a high
rhythm amplitude and a prominent nocturnal maximum.
Melatoninfromextrapineal sites oftenoscillates withconsid-
erably lower amplitudes. Some of the extrapineal sources are,
according to current knowledge, of particular importance,
either in quantitative terms, such as the gastrointestinal
tract (GIT), which contains several hundred times more
melatonin than the pineal gland [1–6], or, with regard
to functional aspects, some areas of the central nervous
system (CNS) [3, 7]a n ds e v e r a ll e u k o c y t e s[ 1, 3, 8, 9]. The
physiological signiﬁcance of most other sites of melatonin
biosynthesis is poorly understood. Melatonin is not secreted
in substantial amounts from most of the extrapineal sites,
or only under speciﬁc conditions. A well-known example
is its postprandial release from the GIT, during which
relatively high quantities can enter the circulation, where
they remain only for a short period of time and are
chronobiologically rather irrelevant [5, 6, 10, 11]. Thus,
melatonin is not only a pineal hormone but also has
additional functions as a local tissue factor and leukocyte-
derived cell hormone with paracrine and autocrine actions
[12]. Moreover, melatonin shows properties of a powerful
antioxidant, at suﬃciently high concentrations as a direct
radical scavenger [13–15], but, at lower, near-physiological
levels, as a regulator of redox-relevant enzymes [1, 6, 15,
16], suppressor of prooxidant excitatory and inﬂammatory
processes [3, 6, 16–19] and as a mitochondrial modulator
[18–25]. With regard to the pathophysiological importance
of mitochondrial dysfunction [18, 24, 26–29]a n dt or e p o r t s
on intramitochondrial accumulation of melatonin [25, 30],
it may be suggestive to assume a particular relevance of
especially this latter property.
Thefunctionalcomplexityofmelatonin’sactionsextends
to the multiplicity of target cells [3] and to signal transduc-
tion mechanisms [31], which are much more diverse than
originally believed. In humans, a classic site of action is2 The Scientiﬁc World Journal
the hypothalamic circadian pacemaker, the suprachiasmatic
nucleus (SCN). This structure is a major site at which
melatonin exerts its chronobiotic, that is, phase shifting, and
its sleep-inducing eﬀects. However, neither circadian phase
shifts nor sleep initiation are exclusively restricted to the
SCN. Findings on melatonin-induced changes in peripheral
circadian oscillators have been recently summarized [32].
Sleep induction by melatonin also comprises thalamic eﬀects
that are detectable in the promotion of sleep spindles [33–
35]. Nevertheless, the presence of particularly high densities
of membrane-bound, G-protein-coupled melatonin recep-
tors (GPCRs) in the SCN strongly supports the premier
signiﬁcance of this structure in receiving and transmitting
the melatonin signal. In mammals, two melatonin-binding
GPCRs exist, MT1 (= Mel1a = MTNR1A) and MT2 (Mel1b =
MTNR1B), and both of them are present in the SCN of most
species. In the human SCN, however, MT2 seems to be either
absentoronlyexpressedatverylowlevels[3].AlthoughMT2
is mainly responsible for phase shifting in other mammals,
the human circadian master oscillator is reset by melatonin
[36, 37], which may be explained by the observation that
both receptors can, to some degree and in some organs,
mutually substitute for each other [3, 31]. Outside the
SCN, MT1 and/or MT2 receptors have been detected in
numerous tissues, such as other areas in the CNS, pituitary,
duodenum,colon,caecumandappendix,gallbladderepithe-
lium, parotid gland, exocrine pancreas, β cells of endocrine
pancreas, breast epithelium, myometrium, placenta, gran-
ulosa and luteal cells, kidney (fetal), cardiac ventricular
wall, aorta, coronary and cerebral arteries and other parts
of peripheral vasculature, brown and white adipose tissues,
platelets, and various immune cells (summarized in [3]).
Additionally, other binding sites, in particular, presumed
nuclear receptors, such as the splice variants a, b, and d
of RORα (retinoic acid receptor-related orphan receptor-α)
and RORβ (= RZRβ), are widely distributed [3, 38]. RORα
is almost ubiquitously expressed, with particularly high
levels in T- and B-lymphocytes, neutrophils, and monocytes,
whereas RORβ is found in brain, pineal gland, retina, and
spleen. For other binding sites related to calcium-dependent
metabolism, mitochondria, and detoxiﬁcation of aromates,
see [3, 31]. Via its receptors, melatonin exerts eﬀects on
the secretion of various other hormones, either directly or
indirectly by inﬂuencing the circadian multioscillator system
[32]. Moreover, countless publications have demonstrated
antioxidant actions in numerous tissues, which may, in the
experimental settings, be partially receptor independent. As
far as they concern eﬀects on antioxidant enzymes and
mitochondrial function, they should be largely explained
by receptor-dependent regulation mechanisms that can be
activated at physiological melatonin concentrations.
The remarkable pleiotropy of this methoxyindole, being
a regulator of numerous functions in many tissues and cells,
indicates that melatonin deﬁciency or dysfunction of mela-
tonin signaling leads to a plethora of consequences, which go
far beyond sleep diﬃculties. Results on receptor knockouts
in animal experiments and human gene polymorphisms of
MT1,M T 2, and melatonin biosynthetic enzymes indicate an
association of melatonin deﬁciency and dysfunction with
numerous diseases, as diﬀerent as forms of cancer, metabolic
syndrome, diabetes type 2, rheumatoid arthritis, and various
mood disorders (summarized in [32]).
2.Age- andDisease-Related
Melatonin Deﬁciency
Melatonin deﬁciency has been mainly investigated in the
pineal gland, circulation, saliva, cerebrospinal ﬂuid, and, by
measuring the metabolite 6-sulfatoxymelatonin, urine. The
nocturnal melatonin peak is regularly observed to decrease
during aging, though with considerable interindividual
variability [39–44]. In aged individuals, the nighttime values
are frequently almost indistinguishable from those obtained
during daytime. However, daytime values can decrease
during aging as well. As long as a melatonin rhythm is
detectable, the nocturnal peak is frequently phase advanced
in the elderly relative to young individuals [43]. All these
changes can be caused by an aging-related deterioration of
the circadian pacemaker or of the neuronal transmission
to the pineal, similar to that observed in neurodegenerative
disorders [43–46], or may result from pineal calciﬁcation
[41].
Decreased levels of melatonin, which exceed those ob-
served during normal aging, have been repeatedly described
in neurodegenerative disorders, especially in Alzheimer’s
disease and other types of senile dementia [47–52]. In many
aﬀected individuals, the melatonin rhythm is practically
abolished. These declines seem to be, in many cases, the
consequence of SCN degeneration. Tissue destruction in the
SCN or in the pineal gland that leads to reduced melatonin
secretion and to sleep disturbances has been also observed
in other cases. This was reported, for example, for juvenile
hamartomas, which cause precocious puberty [53], and for
craniopharyngiomas [54–56].
However, decreases in melatonin levels have been also
reported to occur in many diseases and disorders without
apparent SCN degeneration or destruction. These cases,
which may appear unexpected from a mechanistic point of
view, include neurological and metabolic conditions, such as
diabetes type 2 and general insulin resistance, migraine and
other forms of severe pain, and also certain types of cancer
[57–80]( T a b l e1). For further details, see [3, 32].
3. Light-InducedSuppression of Melatonin
Health problems may also arise in conjunction with noc-
turnal light, which is particularly relevant in shift work.
Nocturnal illumination is known to acutely suppress mela-
tonin formation and secretion by the pineal gland [81], an
eﬀect that should not be confused with the perturbation
of the circadian system [40, 82]. In addition to numerous
preclinical investigations, studies in humans have addressed
the roles of light intensity, duration, and spectral properties
[83–87]. Moderately reduced levels of melatonin or 6-
sulfatoxymelatonin have been reported to occur in the arctic
[88, 89]a n da n t a r c t i cs u m m e r[ 90, 91]. However, their
rhythms are maintained, but sometimes phase shifted. Apart
from an assumed relation to an increased frequency ofThe Scientiﬁc World Journal 3
Table 1: Diseases and disorders that cause decreases in human∗ melatonin secretion independently of apparent tissue destruction in SCN
or pineal gland.
Disease/disorder Comments References
Schizophrenia Only in a subpopulation [57, 58]
Multiple sclerosis with major depression In major depression alone, mostly phase shifts instead of decreases [59–62]
Primary obsessive-compulsive disorder [63]
Meni` ere’s disease Relationship to stress by tinnitus and vertigo? [64]
Fibromyalgia Studied in women [65–67]




Nonsmall cell lung cancer In part caused by pain? [76]
Acute intermittent porphyria Further decreased by seizures [77, 78]
Diabetes type 2 [79, 80]
∗For preclinical ﬁndings of these and other diseases or respective animal models see [3].
migraine [92], these changes do not seem to be of higher
pathological relevance.
Particularly blue light is highly eﬀective in suppressing
melatonin, which is explained by the spectral sensitiv-
ity of melanopsin-containing retinal ganglion cells. These
transmit, in parallel with a smaller contribution by green-
absorbing cones, the photic information to the SCN [93–
95] and from there to the pineal gland. In shift workers, the
transient melatonin deﬁciency induced by nocturnal light
is not compensated during later sleep phases for reasons of
temporal position of the circadian clock. The consequences
of reductions in the levels of the pineal hormone will be
discussed in following sections.
4.Dysfunctionof Melatonergic
Signal Transduction
In humans, the evidence for disease-associated dysfunction
of melatonin signaling is mainly based on changes in
receptor densities or receptor polymorphisms. Decreased
receptor expression can, of course, be the consequence
of degenerative, in particular, neurodegenerative processes.
In patients with Parkinson’s disease (PD), MT1 and MT2
expression declines especially in the substantia nigra and
the amygdala [96]. Decreases in MT1 and MT2 densities
were observed in cerebral cortex and pineal gland of patients
with Alzheimer’s disease (AD) [97]. They also showed
reduced expression of MT2 in hippocampus [98] and retina
[99], and of MT1 in the SCN [46, 100]. However, MT1
density was reported to increase in pyramidal neurons
of the hippocampal layers C1–C4 [101]. Whether or not
this reﬂects a compensatory action, and to what extent
this is associated with diﬀerences in signal transduction
mechanisms (cf. [31]), remains to be clariﬁed. Increases in
MT1 expression were also observed in the cerebrovascular
system, especially in intrahippocampal arteries [102]. Since
MT1 and MT2 exert opposite actions in the vascular system,
that is, activation of MT1 causing vasoconstriction, MT2
vasodilation [103–105], an imbalance between MT1 and
MT2 signaling may indicate a dysregulation of cerebral
blood ﬂow [44, 102]. Indeed, lowered cerebral perfusion
and hemodynamic microcirculatory insuﬃciency have been
discussed as part of the AD pathophysiology [106]a n dm a y
be induced by rises in MT1 expression.
Progressive reductions in receptor densities can be
interpreted as a consequence of degeneration. Nevertheless,
they may contribute to the severity of the disease. In AD,
these alterations are accompanied by an SCN dysfunction,
which also leads to a gradual disconnection of the pineal
gland from its major input [45]. Moreover, the ongoing loss
of melatonin receptors in late AD stages reduces the chance
of alleviating some AD symptoms, such as sundowning
and disturbed sleep, by melatonergic treatment, which is
moderately possible in earlier stages [107–109].
Impaired melatonin signaling may be also deduced from
polymorphisms of melatonin receptors. A large body of
evidence for an association of MT2 variants with a risk
for diabetes type 2 has meanwhile accumulated (recently
reviewed in [32]). Although the disease is multifactorial and
the polymorphism only indicates a statistical probability,
these ﬁndings shed light on the importance of melatonin in
the maintenance of optimal functioning and health. More-
over, this view is supported by changes in insulin secretion,
as observed in MT2 variants [110], and by corresponding
results from animal models, including receptor knockouts
[3, 32]a n de ﬀects of melatonin on the PKCζ/Akt/GSK3β
signaling pathway [111].
MT2 polymorphisms have been also related to rheuma-
toid arthritis [112] and, in combination with other risk
factors, to adolescent idiopathic scoliosis [113], ﬁndings that
may require further support by additional studies (cf. [32]).
MT1 polymorphisms have been associated with polycystic
ovary syndrome, including secondary eﬀects on plasma
glucose and insulin resistance [114], schizophrenia, as well
as schizophrenia-related symptoms of insomnia [115].
Other polymorphisms that may be related to melatonin
concern the nuclear receptor genes, RORα (= RORA) and
RORβ (= RORB = RZRβ). On the one hand, these receptors
are considered as melatonin binding sites [3, 31, 38], but
they also represent factors that interact with the circadian4 The Scientiﬁc World Journal
core oscillators, sometimes in a tissue-speciﬁc manner, and
potentially also in a melatonin-independent way [32]. Thus,
melatonin-independent actions of RORα or RORβ that
involve central and peripheral circadian oscillators cannot
be distinguished from eﬀects of melatonin solely on the
basis of polymorphisms. Because of the latter possibility,
and also with regard to eﬀects of melatonin on central and
peripheral oscillators [32], pertinent ﬁndings shall, at least,
be mentioned. RORα polymorphisms were reported to be
associated with various subforms of depression [116, 117],
though with some methodological limitations (cf. [32]), and
macular degeneration [118, 119]. An RORβ polymorphism
indicated a relationship to bipolar disorder [120]. It will be
of future importance to clarify the involvement of altered
melatonin signaling in RORα and RORβ variants.
5. Consequences of Melatonin Deﬁciency
With regard to melatonin’s orchestrating role [1–3, 32],
a plethora of eﬀects can be expected to result from its
deﬁciency. The consequences are not only evident in the
CNS but extend to numerous other organs. In part, they are
related to disturbances of the circadian oscillator system, but
additional defects of diﬀerent nature may also arise.
In the CNS, membrane and nuclear receptors as well as
other, poorly investigated putative melatonin binding sites
are widely distributed. However, the functional signiﬁcance
is only clear in a few aspects. The most frequently studied
role of melatonin concerns the SCN. In mammals including
the human, melatonin released from the pineal gland is
notably both an output factor steered by the SCN, via
a known neuronal pathway and an input factor feeding
back to the SCN. These aspects, and especially the roles
of melatonin receptors in this hypothalamic structure, have
been frequently reviewed, but mostly in relation to the
controlofthecircadianpacemaker[105,121–124].Aspeciﬁc
eﬀect of melatonin at the SCN is related to sleep. Of
course, this action is intertwined with the phase control
of the master clock but can be discussed separately, in
particular, with regard to sleep initiation. The onset of
sleep is favored by MT1-dependent actions at the SCN that
are further mediated to the hypothalamic sleep switch, a
structure that responds in an on-oﬀ mode. On the basis of
mutual inhibition, it alternately activates either wake-related
neuronal downstream pathways that involve locus coeruleus,
dorsal raphe nucleus, and tuberomammillary nucleus or,
under the inﬂuence of melatonin, sleep-related pathways
via the ventrolateral preoptic nucleus [125, 126]. However,
other brain structures, in which melatonergic receptors are
also expressed, are additionally involved. For instance, the
thalamus contributes to the soporiﬁc eﬀects of melatonin
by promoting spindle formation, which is characteristic for
the transition from stage 2 sleep to deeper sleep stages and
requires a thalamocortical interplay [33, 34, 127]. Although
sleep temporally coincides in humans with high nocturnal
melatonin levels, persistent eﬀects of melatonin on sleep
maintenance are less evident. Nevertheless, low nocturnal
melatonin is, independently of its speciﬁc causes, generally
associated with sleep diﬃculties [65, 128–131].
Elderly insomniacs exhibit strongly decreased levels and
rhythm amplitudes of the excretion product, 6-sulfatoxyme-
latonin, compared to individuals of same age without sleep-
ing diﬃculties [128], but this phenomenon is not restricted
to individuals of advanced age [3]. In cases of pediatric
survivors of craniopharyngioma surgery, the resulting lack
of melatonin secretion was associated with inappropriate
daytime sleep and nocturnal awakenings [54–56]. A per-
turbation of the circadian system may contribute to these
symptoms but does not fully explain them, since the rhythm
of sleep/wakefulness was evident in the actograms [56].
Nocturnal sleep deﬁcits are compensated by the homeostatic
drive to sleep and can lead to daytime somnolence as
well. Similar changes have been observed after pinealectomy
[131], although exceptionally a lengthening of nighttime
total sleep duration has also been observed, which was,
however, mainly caused by an increased REM sleep duration
[132]. Other cases, in which the circadian system was
predominantly aﬀected, will be discussed in the next section.
Sleep diﬃculties are often accompanying symptoms of
depressive disorders [133–135]. Chronic insomnia has even
been considered as a predictor and, possibly, a triggering
factor for this group of diseases [133, 134]. In fact, sleep
d i s t u r b a n c e sh a v eb e e nr e p o r t e da sap r o d r o m a ls y m p t o m
several weeks prior to the recurrence of a depressive episode
[133]. However, the etiologic heterogeneity of depressive
disorders does not allow to conclude on a general relation-
ship between melatonin deﬁciency, resulting insomnia, and
depression. Nevertheless, this connection may exist in some
subforms. Moreover, decreased melatonin levels can be a
reason for ineﬃcient entrainment and, thus, inappropriate
circadian timing, either with regard to the coupling to
external time cues or to internal phase relationships within
the multioscillator system [32]. Some types of depressive
disorders that are associated with or, possibly, caused by
circadian dysfunction will be discussed below.
In addition to its sleep promoting properties, mela-
tonin exhibits various other sedating, antiexcitatory, and
anticonvulsant eﬀects, which comprise diﬀerent actions,
such as facilitation of GABAergic transmission, modulation
of glutamate receptors, secondary eﬀects by decreases of
cytosolic Ca2+ via GABAc or metabotropic mGlu3 receptors,
interference with neuronal NO synthase, changes in K+
currents, and potentiation of strychnine-sensitive glycine-
induced currents (summarized in [6]). To what extent
these functions are impaired under conditions of melatonin
deﬁciency remains to be studied. This may not be obvious,
as long as individuals are not challenged by diseases, but can
become relevant if excitotoxic and brain inﬂammatory pro-
cessestakeplace,forexample,inneurodegenerativedisorders
or brain infection. Similar considerations may be justiﬁed
for antihyperalgesic, antinociceptive and anxiolytic eﬀects,
which seem to be functionally related to antiexcitatory
actions [3, 6, 136].
Numerous other consequences of melatonin deﬁciency
may be deduced from preclinical studies, mainly conducted
in nocturnally active rodents. Diﬀerences between diurnalThe Scientiﬁc World Journal 5
and nocturnal species have to be considered especially in
all areas concerning neuronal activities, the cardiovascular
system, and physical exercise. In these cases, the applicability
to humans remains to be demonstrated, especially in the
following examples. MT2 knockout mice were reported to
be impaired in hippocampal long-term potentiation [137],
a ﬁnding of interest in terms of neuronal plasticity and
learning. MT1 knockout mice exhibited gradual sensori-
motor deﬁcits and increased times of immobility in forced
swim tests, which is usually interpreted as an indication of
depressed-like behavior [138].
Countless publications have dealt with experimental
melatonin deﬁciency by pinealectomy in animals. Only some
studieswillbeconsideredhere,whicharepotentiallyrelevant
to clinical medicine. In senescent rats, pinealectomy caused
enhanced oxidative damage to membrane lipids, protein,
and DNA in various organs, compared to controls of the
same age [139]. These data are in good agreement with
the amply documented antioxidant properties of melatonin,
which have been demonstrated in numerous organisms and
experimental models [1, 6, 12, 14–17, 19, 25, 140, 141].
Pinealectomy was also reported to increase homocysteine
levels, which might indicate a higher risk of cardiovascular
disease, results that were in line with the homocysteine-
reducing action of melatonin [142]. In models of neu-
rodegeneration, based on focal brain ischemia or glutamate
toxicity, the damaged areas were larger in pinealectomized
rats than in control animals [143].
Thelossofmelatoninasacomponentoftheantioxidative
protection system may be also relevant during light-induced
melatonin suppression in nocturnal shift work [144, 145],
in addition to the perturbation of circadian oscillators.
Similar assumptions have been made with regard to aging.
However, aging is a complex phenomenon during which
primary, lingering processes that include increased free-
radical formation because of progressive mitochondrial
impairments are superimposed by events of deterioration
due to diseases, which lead to secondary impairments [19].
Individual catastrophes such as infarction, stroke, renal
failure, or cancer impair the function of organs and cells and,
thereby, contribute to the acceleration of the more continual
mechanisms of aging, even if treatment is successful. Less
severe diseases, such as subclinical chronic inﬂammation,
may also aﬀect the health state and lead to a more rapidly
progressing senescence. Aging itself and many age-related
diseases are associated with increases in free-radical forma-
tion, along with a higher vulnerability to oxidative damage
and less eﬃcient repair mechanisms [19, 146–152]. On this
background, it seems attractive to assume that melatonin,
which acts as a direct and indirect antioxidant, improves
mitochondrial function, and has some additional cell-
protective and antiiﬂammatory properties, may antagonize
senescence. Correspondingly, melatonin deﬁciency might
cause an acceleration of aging and increase the likelihood of
developingage-relateddiseases.However,thedirectevidence
for this relationship is still insuﬃcient. On the one hand,
the health state of experimental animals treated during
aging with melatonin is usually better, as referred to as
the “Methuselah syndrome” [153]. Old melatonin-treated
rodents display a higher mobility, a glossy fur, absence of
skin inﬂammations, and low osteoporosis, compared to age-
matched controls [6]. These ﬁndings indicate that melatonin
deﬁciency may promote age-related diseases.
On the other hand, life extension by melatonin is not
that much apparent in those rodent strains which do not
die from cancer [6, 153]. Thus, a longer lifespan observed
in mice strains that predominantly die from cancer reﬂects
chemopreventive actions of melatonin rather than a true
antiaging eﬀect [6]. However, a prolongation of life by
melatonin was demonstrated in the senescence-accelerated
SAMP8 mouse strain [154] .T h e s em i c ea r em o r ev u l n e r a b l e
tooxidativestress,butamajorquestionisthatofwhetherthe
processes responsible for the more rapid aging are identical
with the normal causes of aging. As argued elsewhere [19],
other progerias, for example, of a laminopathic type, do not
reﬂect normal aging.
Since melatonin is multiply involved in immunodulation
[1–3, 6, 9, 155, 156], and since the immune system is dete-
riorating by age [157–159], melatonin deﬁciency may also
be assumed to contribute to immunological aging. However,
the role of melatonin is highly complex in this regard.
First, the methoxyindole exerts both immune stimulatory
and antiinﬂammatory properties and can act in a pro-
or antioxidant fashion, depending on leukocytes aﬀected
and conditions of infection or inﬂammation. Moreover,
melatonin is synthesized by several types of leukocytes [1, 3,
8, 9, 155]. Although many immune cells express melatonin
receptors [3, 6, 9, 155] and can, therefore, respond to the
circulating hormone, a decrease in melatonin secretion by
the pineal gland does not necessarily imply losses of immune
functions, as far as they are based on paracrine and autocrine
actions of melatonin produced by leukocytes. Nevertheless,
the relationship between melatonin and the immune system
during aging remains to be an issue worth of future eﬀorts.
Immunological aspects of melatonin extend to onco-
logical questions. Melatonin deﬁciency has, in fact, been
discussed in terms of the risk of developing certain types of
cancer. Oncostatic actions of melatonin have been observed
in various experimental models and include growth and
apoptosis of malignant cells [160–165]. These ﬁndings
clearly exceed the immunological role and primarily con-
cern signaling mechanisms in the respective cancer cells.
Nonetheless, the development of tumors from transformed
cells may be favored under conditions of melatonin deﬁ-
ciency, when immunomodulation by the pineal hormone
has declined. In humans, melatonin deﬁciency has been
attributed to a higher incidence of prostate [65],endometrial
[75, 166], and breast [65, 167] cancers. It has remained
unclear whether the decreases in melatonin have occurred
prior to the disease and are contributing factors to tumor
development or represent secondary changes induced by
the tumor. Moreover, it remains to be clariﬁed whether, or
to which extent, the insuﬃcient melatonin levels and the
perturbations of the circadian system are decisive.
An emerging ﬁeld of melatonin research concerns
metabolic disorders, obesity, prediabetic states, diabetes type
2, and general insulin resistance [3, 32, 80, 168]. Numerous6 The Scientiﬁc World Journal
data from preclinical studies have shown a regulation of
insulin and glucagon release by melatonin. Direct evidence
foraninvolvementofthemethoxyindoleindiabeteshasbeen
obtained in mice, in which insulin resistance is induced by
knockout of the MT1 receptor gene [169]. Corresponding
data were reported for obesity and prediabetic states. Aging
rodents showed increases in visceral adipose tissue that
were correlated to a decline of melatonin [1]. Weight gain
induced in old- or middle-aged rats by high-fat diet, by
ovariectomy, or, notably, by pinealectomy was reversed by
melatonin, with concomitant normalizations of insulin and
leptin levels [170–175]. Similar activities were reported for
the synthetic melatonergic agonists NEU-P11 [174]a n d
ramelteon[176].Inhumans,themainevidencewasobtained
in several studies which demonstrated an enhanced risk
for diabetes type 2 in variants of the MT2 receptor gene
( s u m m a r i z e di n[ 32]). Collectively, all pertinent ﬁndings
indicate that high nocturnal melatonin and intact melatonin
signaling are in favor of avoiding diabetes type 2, despite
the chronobiological diﬀerences between nocturnally active
rodents and humans.
With regard to the numerous sites of melatonin receptor
expression within the body, many additional consequences
may arise from melatonin deﬁciency and be clinically
relevant. A high number of data, which would by far exceed
the scope of this review, exist for eﬀects of melatonin in
other tissues, including the cardiovascular system, bones,
other endocrine glands, and visceral organs. However, direct
evidence, on a clinical basis, for a causative role of melatonin
deﬁciency in their respective diseases would be required for
deﬁnite judgments.
6. MelatoninandCircadianDysfunction
Circadian dysfunction can result from diﬀerent causes, such
as (i) mutations/variants of circadian core oscillator genes,
(ii) impaired light input pathways because of blindness or
age-related reduction of photoreception, (iii) inadequate
artiﬁcial lighting, as far as it is too dim and poor in short
wavelengths,or(iv)degenerationoftheSCNortheneuronal
connections from the retina to the SCN. With regard to
peripheral oscillators, epigenetic changes in the promoters of
core oscillator genes, as frequently observed in cancer, can
likewise lead to local circadian dysfunction [32].
The role of photoreception requires some distinctions.
Visual blindness does not necessarily cause circadian mal-
function, especially not if intact melanopsin-containing
retinal ganglion cells and the connection to the SCN are
retained. On the other hand, circadian photoreception may
signiﬁcantly decrease in the aging eyes of sighted persons
because of pupillary miosis and reduced crystalline lens
transmission in the short wavelength range. This can already
lead to circadian disruption and increase the incidence of
sleep problems, aﬀective disorders, metabolic syndrome, and
other systemic diseases [177].
Physiologically unfavorable deviations of rhythmicity
can be identiﬁed at the level of the circadian oscillators, their
phasing by external time cues, and their internal coordi-
nation within the multioscillator system. These alterations
occur under the following conditions [32, 178, 179]. (i)
Reductionintheamplitudeofasingleoscillator,forexample,
during aging and under weak zeitgeber strength, especially
in persons with visual impairments, night-eating syndrome,
or insulin resistance. A ﬂattened oscillation has a reduced
capability of interacting with other oscillators, which results
in the loss of stable internal phase relationships. Moreover,
the coupling to external time cues may be impaired. (ii)
Phase shifts that lead to internal circadian disruption if the
synchronizingsignalaﬀectsthevariousoscillatorsdiﬀerently.
If a light-sensitive oscillator is reset under conditions of
rotating shift work or light at night because of other reasons,
other oscillators that are synchronized by the onset of
darkness or by nonphotic time cues may not follow and
become uncoupled. (iii) The central pacemaker is poorly
synchronized with the external cycle, as known under the
term “free-running disorder” (FRD). Deviations in the
spontaneous period of the central pacemaker can either lead
to a nonsynchronized free-running oscillation or to a poorly
coupled rhythm that shows relative coordination with the
environmental cycle. Additionally, the internal coordination
withinthemultioscillatorsystemmaybedisturbed.FRDmay
be either caused by impaired photoreception, as observed in
some blind individuals [180–185], or by genetic predisposi-
tions. Despite the existence of data from animals related to
mutations in clock genes and other factors aﬀecting oscilla-
tors, the knowledge on respective human polymorphisms is
limited. However, genetic causes may be deduced from the
existence of FRD in sighted individuals with a disease onset
during youth [186–188]. In humans, more is known about
the genetic basis of extreme morningness or eveningness,
symptoms that are associated with pronounced deviations
of the spontaneous, free-running period observed in the
absenceofexternalzeitgebers.Inthesecases,synchronization
with external time cues is still possible, but the phasing
of rhythms deviates from normal and results in circadian
rhythm sleep disorders (CRSDs). Polymorphisms in the core
oscillator genes Per2 and Per3 (period 2 and 3)h a v eb e e n
identiﬁed as being causative of some CRSDs [187, 189], but
mutations in other clock genes may lead to similar changes
as well.
The coupling strength of oscillators within the organism
diﬀers between individuals. This is already evident in the
classic cases of humans investigated in isolation. A certain
number of subjects deprived from external time cues shows
the phenomenon of internal desynchronization, as ﬁrst
described by Aschoﬀ and Wever [190], whereas others do
not. The desynchronization is reﬂected by strongly deviating
spontaneous periods of the sleep/wakefulness and body
temperature rhythms. However, the coupling between the
two oscillators is not entirely abolished, since they show
relative coordination, that is, they partially attract each
other for a few cycles but, thereafter, dissociate again. In
these individuals, the internal coupling force is too weak
to maintain robust coordination under free-running con-
ditions. Deviations in coupling of free-running oscillators
are even normally observed in individuals without internal
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between sleep/wakefulness and temperature rhythms is
altered, although both clocks oscillate with the same period.
The interindividual variations indicate that internal
uncoupling may more easily occur in some subjects than
in others, when rhythms are either perturbed or weakened.
Malcoordination of oscillators within the organism’s com-
plex clockwork seems to be of pathological relevance, when
this occurs under conditions of normal life. This may play
a role in some disorders, in which infradian [191] cycles,
that is, rhythms with periods of several or many days,
becomeapparentinadditiontoother,physiologicallynormal
infradian rhythms (such as circaseptan or circatrigintan
cycles [191]). The atypical long cycles, which result from
relative coordination of weakly interacting oscillators, are
particularly observed in mood and performance. In practice,
however, these long cycles are diﬃcult to distinguish from
poor synchronization of a single oscillator to an external
time cue, which would reﬂect relative coordination between
endogenous and zeitgeber cycles. In any case, physiologically
atypical infradian rhythms are indicative of disturbances in
the circadian oscillator system. Moreover, a weak coupling
of an oscillator to the external cycle may already suﬃce for
the development of symptoms if the rhythm remains syn-
chronized but is strongly dysphased. Alterations of that type
are likely present in bipolar and seasonal aﬀective disorders
[192–196], assumptions that have gained support by epi-
demiological studies on core oscillator gene polymorphisms
(summarized in [32]). Changes of this kind can be expected
to result in sleep diﬃculties. However, the reverse conclusion
that sleep disturbances are indicative of a malfunctioning
circadian system is not generally possible [197]. In major
depressive disorder, which is typically associated with sleep
problems, no convincing evidence exists for the involvement
of the circadian system [198], although this may not be
entirely excluded in some subtypes.
Changes in the circadian multioscillator system may be
sometimes rather cryptic but become evident by molecular
analysesoftherhythmicexpressionofcoreoscillatorgenes.It
is important to be aware that multiple oscillators do not only
exist in diﬀerent organs but also in the same organ, in which
parallel oscillations are based on the alternate expression of
orthologs or paralogs of the clock genes [32]. Again, the
coupling between these parallel oscillators can be aﬀected
by pathophysiological or, in animal models, experimental
disturbances. These approaches provide valuable evidence
for the importance of melatonin in the internal coordination
of rhythms. In the rat SCN, pinealectomy leads to an abnor-
mally large phase diﬀerence between the parallel oscillations
in the expression of the alternate core oscillator genes Per1
and Per2. This change is reversed by melatonin adminis-
tration [199]. The relevance of melatonin has also been
demonstrated in another autonomous circadian oscillator
of the CNS, the murine retina. In the melatonin-proﬁcient
mouse strain C3H, prominent oscillations were observed in
the core oscillator proteins PER1 and CRY2 (cryptochrome
2) as well as in CREB phosphorylation, whereas a signiﬁcant
rhythmicity of these factors was absent in the melatonin-
deﬁcient mouse strain C57BL [200]. Moreover, knockouts of
either MT1 or MT1 and MT2 produced considerable phase
shifts in the circadian rhythm of PER1, without abolition of
the rhythm itself [201].
In the autonomous clock of the adrenal cortex, PER1,
CRY2, and BMAL1 (brain and muscle ARNT-like 1; alias
ARNTL)protein levelsoscillatedwithsubstantialamplitudes
in the melatonin-proﬁcient mice, whereas the deﬁcient ani-
mals did not exhibit robust rhythms in these core oscillator
proteins [202].
In cultures of murine striatal neurons, the knockout of
the melatonin receptor MT1 abolished melatonin-induced
changes in the expression of various core oscillator genes
[203]. In cultured mouse cerebellar granule cells treated
with nanomolar concentrations of melatonin, the deletions
of either MT1 or MT2 caused losses in the inhibition of
forskolin-stimulated cAMP synthesis and cFos expression, as
well as in the inhibition of Akt (= PKB) activation. These
knockouts were also reported to turn the normally observed
suppression of the MAP kinase ERK into an upregulation
[204].
In humans, the chronobiological role of the pineal
hormone became also evident in several studies. A child
with congenital melatonin deﬁciency exhibited a non-24-
hour sleep-wake rhythm, which was corrected by melatonin
treatment [205]. An entirely diﬀerent case of melatonin deﬁ-
ciency was caused by a defect mutation in the sepiapterin-
reductase gene [206]. In this patient, serotonin synthesis was
impaired and the poor precursor availability prevented the
formation of substantial amounts of melatonin. Although
serotonin has its own role in sleep regulation, the symptoms
of hypersomnia, a circa 12-hour sleep-wake rhythm, and
hyperphagia, were normalized by melatonin treatment and
were,thus,attributedtothedeﬁciencyofthepinealhormone
[206].
Another congenital disorder, the Smith-Magenis syn-
drome (SMS), is not only associated with developmental
andneurobehavioral abnormalities butalsocausesanalmost
inverted melatonin rhythm and sleep diﬃculties [207, 208].
SMS is caused by haploinsuﬃciency of the transcription
factor RAI1 (retinoid acid induced 1) [209, 210], whose
relationship to melatonin and circadian rhythmicity is
unclear. At least, the sleep-related symptoms have been
alleviated by suppressing melatonin synthesis during the day
by a β1-adrenergic blocker and melatonin administration in
the evening [211, 212].
Collectively, all these ﬁndings indicate that melatonin is
required in multiple ways in adjusting circadian rhythms, by
providing a feedback to the SCN and also by safeguarding
phase relationships between parallel oscillators in the SCN
and between various autonomous clocks of the multioscilla-
torsystem.Thisconclusionisfurthersupportedbyanumber
of reports on eﬀects of melatonin on the expression of
core oscillator genes and on resetting of rhythms in various
peripheral tissues, as recently summarized [32].
7. Options for Treatment
With regard to treatment, it is important to distinguish
between disorders in which only short actions of melatonin
are required and those in which a substitution therapy aims8 The Scientiﬁc World Journal
to replace insuﬃcient nocturnal levels of the hormone over
an extended period throughout the night. The necessity of
this distinction results from the short half-life of melatonin
in the circulation, which is, depending on time of adminis-
trationandotherfactors,intherangeof20–45min[35,213].
Extended melatonergic actions are, therefore, only possible
with prolonged release formulations of the natural hormone
or with synthetic, longer-acting agonists.
Only a short action of melatonin is required in the case
of sleep onset diﬃculties. Melatonin is known to reduce
sleep onset latency, frequently determined as LNA (latency
to nonawake) or, by polysomnography, as LPS (latency
to persistent sleep). Both melatonin and all eﬃcacious
melatonergic agonists exhibit this property [35, 197, 214]. In
contrasttorecommendeddosesofsyntheticagonists,suchas
4or8mg/d(ramelteon)and25mg(agomelatine),melatonin
promotes sleep onset already at doses of 0.1–0.3mg/d
of an immediate release formulation [215]. Consequently,
melatonin should be preferred as long as no additional
eﬀects are intended, such as support of sleep quality or
maintenance. The natural hormone has without any doubt,
advantages in terms of tolerability, physiological metabolism
and, perhaps, MT1/MT2-independent eﬀects that should be
absent in the synthetic drugs [7, 197].
Another area in which short actions are suﬃcient
concerns the chronobiotic, that is, phase-shifting prop-
erties of melatonin. Resetting of the circadian oscillators
is recommended or even a requirement in the case of
rhythm perturbations. These may have been induced either
(i) externally by light at night or transmeridian ﬂights
or (ii) by clocks poorly coupled to the environmental
cycle or internally to other clocks, in cases of dysphasing
or desynchronization within the multioscillator system.
Insuﬃcient coupling may result from ﬂattened oscillations,
especially under conditions of reduced melatonin secretion
due to age or disease. Phenomena such as relative coor-
dination, internal desynchronization, and abnormal phase
relationships between parallel oscillators have been poorly
investigated on a systematic basis, but they seem to be
involved in impairments of physical and mental ﬁtness as
well as bipolar and seasonal aﬀective disorders [192–196]. As
far as circadian malfunctioning is implicated in these mood
disorders, melatonin can be eﬀective in readjusting rhythms
and, thereby, improving symptoms. Similar treatments with
synthetic melatonergic drugs can be expected to be likewise
beneﬁcial, but neither a higher receptor aﬃnity nor a longer
half-lifeisareasonforassumingasuperioreﬃcacycompared
to melatonin.
Circadian oscillators are largely sensitive to the so-called
nonparametricresettingstimuli[216],thatis,changesofsuf-
ﬁcient extent rather than absolute levels of the synchronizer.
Therefore, a short-acting drug can meet the requirements
for phase adjustments. Immediate-release formulations of
melatonin should be suitable, and a need for using synthetic
agonists instead is not apparent. However, such a treatment
has to consider some fundamental chronobiological rules.
Resetting signals are acting according to a phase response
curve (PRC). PRCs describe the dependence of a phase
shift on the circadian phase of stimulus administration.
Typically a PRC contains an advance part, a delay part, and
a silent zone, in which the same signal, which otherwise
causes advances or delays of the rhythm, has no or only
minor eﬀects. In humans, the PRC for melatonin is known
[36, 37]. The time of melatonin administration according to
the PRC is of utmost importance. Readjustment of rhythms
by melatonin will only be achieved if it is given in an
appropriate, suﬃciently sensitive phase within the circadian
cycle. If the rhythm is dysphased because of poor coupling
to synchronizers, it may take several days more until the
oscillation has attained the desired phase. Disregard of these
chronobiological fundaments may lead to false conclusions
on ineﬃcacy.
It should also be noted that the circadian rhythms can
be eﬃciently reset by light, as long as light perception in
the blue range and neuronal connections to the SCN are
not impaired. Light therapy is, thus, an option in these
cases, whereas, under conditions of poor accessibility of the
SCN to light signals, melatonin may be preferred. In some
individuals, a combination of light and melatonin in the
diﬀerent, respective phases may be suitable as well. Apart
from jet lag, attempts of resetting the circadian oscillators
by melatonin and/or light may be especially successful in
cases of bipolar and seasonal aﬀective disorders, as far as they
can be attributed to rhythm perturbations [32, 192–196].
Whether or not melatonin has an additional, MT1/MT2-
independent eﬀect not exerted by synthetic agonists remains
to be clariﬁed. A polymorphism of the RORβ (= RORB =
RZRB) gene has been attributed to a risk of bipolar disorder
[120]. Melatonin is believed to act as an RORβ ligand [38],
and RORβ knockout mice showed atypical PRCs and a
lengthened circadian period [217, 218], but the possibility
exists that RORβ acts on the circadian core oscillator in a
melatonin-independent way [32]. Since melatonin phase-
shifted circadian rhythms in the RORβ knockouts, though in
an atypical manner, Masana et al. [218] had concluded that
melatonin is not involved in the deviations because of RORβ
deﬁciency.
Thesituationisentirelydiﬀerentifareplacementtherapy
is desired in aged individuals or patients suﬀering from
diseases that are associated with decreases in melatonin
levels. Because of the short half-life, immediate-release
formulations of melatonin cannot aﬀord a satisfactory
substitution.Withregardtomelatonin’ssuperiortolerability,
a prolonged-release tablet of the pineal hormone may be
tested ﬁrst [35], such as Circadin, which is approved in
Europe by EMEA for the treatment of insomnia in patients
aged 55 years and over. If the improvements are too
poor, longer-acting synthetic MT1/MT2 agonists may be
tested. To date, two drugs of this type have been licensed,
ramelteon (Rozerem = TAK-375) for treatment of insomnia
in the USA, and agomelatine (Valdoxan) for treatment
of major depressive episodes (MDE) in adults in Europe.
Ramelteon has a higher aﬃnity than melatonin to MT1 and
MT2 receptors and is devoid of relevant aﬃnities to other
receptors, whereas agomelatine exhibits similar aﬃnities to
MT1 andMT2 asmelatoninbutactsadditionallyasa5-HT2C
antagonist,apropertyattributedtoitsantidepressiveactions.
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than melatonin and are, thus, longer acting. For comparison
of aﬃnities, pharmacokinetics, metabolism, and eﬃcacy of
melatonin, ramelteon, and agomelatine, see [35].
A few remarks seem to be necessary concerning the use
of the synthetic melatonergic agonists. First, the therapeutic
limits of the respective licenses should be considered,
which excludes some uncontrolled treatments. Moreover,
the deviating characteristics of the synthetic compounds are
of importance, especially with regard to metabolism and
drug interactions. The metabolism of ramelteon leads to
several compounds, one of which has unusual properties.
Thismetabolite,referredtoinliteratureasM-II,hasaﬃnities
to MT1 and MT2 of about 10% of ramelteon, but a 2–
5h longer half-life. It can attain concentrations by 20-
to 100-fold higher than the parent compound [35, 215,
219, 220] and, thus, contributes substantially to the overall
eﬀect of the drug. Ramelteon is mainly metabolized by
CYP1A2, CYP2C9, and CYP3A4, and, consequently, other
drugs that inhibit one or several of these isoenzymes,
such as ﬂuvoxamine, ciproﬂoxacin, mexiletine, norﬂoxacin,
azileuton, ﬂuconazole, or ketoconazole, have to be avoided.
For other conditions of concern, see [215]. Although
ramelteon has a higher aﬃnity to the melatonin membrane
receptors and although it acts longer than melatonin, the
recommended doses of 4 or 8mg/day are higher than those
of melatonin prolonged-release (2mg/d). Like melatonin
and other melatonergic drugs, it reduces sleep latency. With
regardtosleepmaintenance,as testedinelderly patients with
primary chronic insomnia, the improvements by ramelteon
were found in a recent review to be highly variable [221].
Despite some statistically demonstrable increases in sleep
duration or sleep eﬃciency, this does not yet imply complete
restoration of persistent sleep throughout the night [221–
223]. Prolonged-release melatonin was rather poorly eﬀec-
tive on sleep duration in this type of patients [35], although
sleep quality, next-day alertness, and measures of quality of
life were moderately improved. In view of these results, one
might conclude that both ramelteon and prolonged-release
melatonin are of some practical value, but that a suﬃcient
replacement therapy has not yet been achieved.
During the last years, the necessity of long-term studies
for ramelteon has been expressed, especially with regard
to hepatotoxicity, micronuclei formation, and mutagenicity.
This should include the metabolite M-II, which attains con-
centrations in the range of one third of the no-eﬀect level for
tumor induction of the parent compound [215, 220]. Several
recent papers indicate long-term safety of ramelteon in their
titles [224–226], but they mainly address adverse events such
as nausea and headache, some hepatological parameters,
lack of residual eﬀects, of rebound insomnia, of withdrawal
symptoms, and dependence for periods of six or twelve
months, but not the absence of mutagenic/carcinogenic
actions over extended treatment.
Agomelatine, which has been licensed only for treatment
of major depressive episodes, displays all the sleep-inducing
and chronobiotic eﬀects known from melatonin [61, 134,
135, 227]. With regard to these properties, it seems similarly
suitable as ramelteon or melatonin. However, the focus on
depressive symptoms leads to problems in justifying treat-
ment and also to some misunderstandings. Again, a distinc-
tionbetweentypesofdepressionbasedoncircadiandysfunc-
tion or on other reasons is important. In the ﬁrst case, the
eﬃcacy of agomelatine cannot be distinguished from those
of other melatonergic agonists of similar receptor aﬃnity.
However,inmajordepressivedisorders,theimprovementsof
symptoms have been attributed to the inhibition of 5-HT2C
receptors [134, 135, 220, 227–230]. However, this property
is not comparable to eﬀects by classic antidepressants. For
this reason, some authors have considered the eﬃcacy of
agomelatine insuﬃcient in major depressive disorder [231–
233]. Moreover, biased publication on the eﬃcacy of this
drug has been criticized [234]. However, it should be noted
that the advantages of agomelatine do not consist in a
superior antidepressive eﬀect, but rather in the combination
of antidepressive beneﬁts with sleep improvements, which
is important because sleep disturbances are often induced
by classic antidepressants [134, 135, 220, 230]. Agomelatine,
being a naphthalene derivative, may also become a matter
of concern under aspects of toxicity. Although it is well
tolerated according to adverse events during short treatment,
absence of rebound insomnia, withdrawal symptoms, and
dependence, we had previously emphasized that a naph-
thalenic compound requires thorough studies on long-term
toxicity, including CYP-related hepatic eﬀects and, eventu-
ally, carcinogenicity [35, 197, 220]. This is not so much a
questionofdruginteractionswithCYP1A2inhibitors,which
have to be avoided in any case, but rather of the formation
of toxic naphthalenic metabolites. Under this aspect, the
high recommended dose of 25mg/d may turn out to be a
disadvantage of agomelatine. This issue has been recently
readdressed. Moderate increases in liver enzymes are rather
common, but serious hepatotoxicity is rare during treatment
of moderate length [231, 233]. It was also criticized that the
riskofhepatotoxicityhadnotbeenprominentlydocumented
in the published studies [232, 234], and oncogenicity of
very high doses in animals experiments [232] should be
taken as a caveat. It should also be noted that agomelatine,
being a melatonergic agonist, can only be administered, for
chronobiological reasons, in the evening. Conclusions on
antidepressive eﬀects cannot be convincingly drawn from
studies conducted in nocturnally active rodents, in which
melatonin is associatedwith the darkphase andactivity. This
reservation is valid for all melatonergic drugs but has been
disregarded by some investigators in models of depression
and anxiety, and even in studies on sleep (for criticism, see
[197]).
In addition to the licensed products, numerous inves-
tigational drugs have been developed, some of which may
have advantages and may be approved in the future [197].
Among these, β-methyl-6-chloromelatonin (= TIK-301 =
LY 156735), tasimelteon, GR 196429, the indane compound
GG-012, several substituted 8-methoxytetralins, double ring
compounds like UCM765 and UCM924, in which halogen
atoms are positioned to avoid CYP-dependent hydroxyla-
tions, and NEU-P11 may be mentioned (for comparisons,
see [197]). The suitability of these compounds will depend
on nontoxicity and superior eﬃcacy compared to other
drugs. Receptor aﬃnities are sometimes in the range of10 The Scientiﬁc World Journal
melatonin, but not rarely considerably lower, which would
require very high doses. Advantages are mostly observed in a
half-life much longer than that of melatonin.
One of these newly-developed drugs, NEU-P11, has been
preclinically studied in another area, which may gain impor-
tance in the future, namely, metabolic disorders including
obesity, insulin resistance, and diabetes type 2 [174]. The
signiﬁcance of melatonin in this complex of disorders and
diseases has become particularly evident during recent years
[3, 32, 80, 168]. A disadvantage of NEU-P11 may be seen
in its relatively low receptor aﬃnity, whereas its half-life
is favorable. In this area, future comparisons with other
melatonergic drugs will be of interest.
8. Conclusion
Melatonin deﬁciency is common in aging and also associated
with various diseases of diﬀerent etiology. Moreover, mela-
toninsecretionissuppressedbynocturnallight,whichcanbe
a matter of concern in shift work. With regard to the multi-
plicity of melatonin’s actions, the consequences of melatonin
deﬁciency extend to numerous physiological functions. If
subnormal melatonin levels are caused by neurodegenera-
tion in the SCN, which controls the mammalian pineal gland
and to which this hormone is feeding back, administration
of the methoxyindole cannot readjust the circadian oscillator
system in full. Eﬀects on some peripheral oscillators are not
excluded, but this has not yet been demonstrated under such
conditions. Eﬀects on other physiological functions that are
accessible independently of the circadian oscillator system,
but not necessarily devoid of normally occurring circadian
oscillations, may still be positively aﬀected by melatonin.
Examples may be found in the areas of immune modulation,
antioxidative protection, correction of metabolic syndrome,
or gastrointestinal functions.
Melatonin dysfunction can result from diﬀerent causes.
Melatonin receptor variants, which have been found to be
associated with risks for various diseases [3, 32], presumably
lead to impaired or incomplete signal transduction. How-
ever, the cell biological details of these changes remain to be
elucidated. Dysfunctions can also arise from abnormalities
of the circadian oscillator system, because of either polymor-
phisms of core oscillator genes that lead to deviatant period
lengths of the rhythms or impaired light input pathways
towards the SCN. Again, gene variants causing exceptionally
long or short periods are associated with risks for various
diseases [32].
Successful treatment of melatonin-related disorders
largely depends on the following criteria. (i) If only short
actions of melatonin are required, improvements are likely.
This is the case in sleep initiation and in disorders with
an etiology of poor synchronization by external time cues
and, perhaps, those characterized by poor internal coupling
within the multioscillator system. This phenomenology
seems to be of relevance in seasonal eﬀective and bipolar
disorders. (ii) Since the SCN is involved in the entrainment
by melatonin, the structural and functional integrity of this
hypothalamic structure has to be suﬃciently preserved. (iii)
Melatonin receptors have to be expressed at fairly normal
levels and signal transduction should not be impaired
because of mutations in the receptor genes.
All the treatments that only require short actions of
melatonin can be successful, under conditions mentioned,
by using relatively moderate amounts of immediate-release
melatonin. Although synthetic melatonergic agonists are
likewise eﬀective in sleep initiation and improvements of
circadian rhythm-related disorders, a need for their use or
a substantial superiority is not evident. The higher recom-
mended doses of the synthetic drugs and the remarkable
tolerability of the natural hormone are clearly in favor
of melatonin. Nevertheless, several contraindications or
possible reasons of concern should be considered prior to
prescription, such as use in children—except of severe or
otherwise intractable cases, during pregnancy, in patients
with autoimmune diseases, liver dysfunctions, medication
with CYP1A2 inhibitors [35], and, unless the issue is
deﬁnitely settled, Parkinson’s disease and irritable bowel
s y n d r o m et y p eI I ,w h i c hh a v eb o t hb e e ni n t e r p r e t e da s
diseases of melatonin overproduction (“melatonin hyperpla-
sia”) [235].
For treatment of disorders that require extended mela-
tonergic actions, melatonin prolonged release formulations
and synthetic longer-acting drugs have been developed. If
judged according to criteria of sleep maintenance, some
improvements can be achieved especially by synthetic
agonists such as ramelteon. Even though these eﬀects
are statistically demonstrable in some studies, this is not
generally so. More importantly, it has to be stated that
the improvements remain rather moderate in their extent,
even if they are signiﬁcant according to formal statistical
criteria.Thesomewhatdisappointingconclusionisthatafull
replacement therapy of melatonin deﬁciency, which restores
high melatonergic activity throughout the night, has not
been successful to a desirable degree. Nevertheless, further
studies may reveal improvements in other physiological
parameters not primarily or directly related to sleep, such
as measures of lipid metabolism, mitochondrial function, or
sensitivity to insulin. Whether or not synthetic drugs will
turn out to be superior to melatonin in these ﬁelds remains
to be demonstrated.
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